CKD-828 + D326 + D337

CKD-828 + D326 + D337 is a fixed-dose combination therapy being studied as CKD-348 for the treatment of hypertension in patients with dyslipidemia. CKD-828 is a well-characterized fixed-dose combination of S-amlodipine (the active isomer of amlodipine, a calcium channel blocker) and telmisartan (an angiotensin II receptor blocker). In the context of CKD-828 + D326 + D337 (CKD-348), the therapy is being evaluated for its blood pressure and lipid-lowering (dyslipidemia) effects, though the exact identities of D326 and D337 are not detailed in publicly available primary literature. The principal developer is Chong Kun Dang Pharmaceutical. Its mechanism relies on the antihypertensive actions of S-amlodipine (vasodilation via calcium channel blockade) and telmisartan (antagonism of angiotensin II at AT1 receptors to reduce vasoconstriction and aldosterone secretion), with possible additional lipid-modification effects from D326 and D337, likely lipid-lowering agents. The therapy is under late-phase (Phase III) clinical trial investigation for patients with both hypertension and dyslipidemia[2][1][3].

Brand names

CKD-348CKD348CKD 348

Other names

CKD-828 + D326 + D337CKD-348CKD348CKD 348